CA-MCAFEE
17.1.2024 06:02:32 CET | Business Wire | Press release
McAfee Corp., a global leader in online protection, today announced findings from its Global Small Business Study which surveyed the owners and IT decision makers at small businesses across six countries to discover their thoughts and behavior around cybersecurity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116065441/en/
Business partners working together (Photo: Business Wire)
The study, conducted in collaboration with Dell Technologies, reveals cybersecurity is one of the greatest concerns of small businesses globally, with 73% of organizations saying it is one of their biggest risks or vulnerabilities. And these fears are justified. The data shows that cyberattacks are on the rise, as 44% of small businesses have experienced a cyberattack, and 17% have experienced more than one. For 67% of the organizations that experienced a cyberattack, the incident occurred in the last two years, indicating that the threat of cybercrime has become more prevalent.
For a small business, even a single cyber incident can be devastating to the bottom line. For small business owners who experienced a cyberattack, 61% lost more than $10,000 dealing with the attack. In addition, more than half (60%) of the business owners and IT decision makers indicated that the cyberattack on their business took a physical or mental toll on them and/or their staff or colleagues. In 58% of the cases, the business lost more than a week of valuable time dealing with IT issues due to the attack.
These cyberattacks have a significant impact on the finances, customer trust, and operating efficiency of small companies, causing customer data (38%), passwords (34%) or other files (34%) to be lost. Many of these attacks (43%) were caused by someone mistakenly downloading malware by clicking on a phishing link and/or opening a malicious attachment.
Unfortunately, small business owners are at a significant disadvantage when faced with malicious messages that are increasingly realistic and frequent thanks to artificial intelligence (AI). AI is a scammer's favorite tool, helping cybercriminals increase the scale, speed and sophistication of phishing and text message scams.
To help reduce AI-related concerns and anxieties about data security, small business owners need AI to beat AI. This cutting-edge technology can work in their favor to proactively protect them in real-time before they even know they have been targeted. For example, the AI-driven technology behind McAfee’s McAfee Scam Protection, proactively blocks dangerous links that appear in text messages, social media, or web browsers and allows users to engage with text messages, read emails, and browse the web peacefully and securely.
Cybersecurity Support and Responsibilities
Many small business owners understand that cyber threats are something they need to plan for and invest in mitigating. Despite their awareness, only about half (48%) of business owners/IT decision makers were fully confident in the ability of their business to prevent cyberattacks. Most small businesses (76%) manage cybersecurity without the help of others outside their business and almost half (45%) said they focus on overall general IT issues more than 7 hours a week.
McAfee and Dell’s Global Small Business Study also found:
- Nearly one-third (24%) of business owners worry about cyberattacks daily.
- Less than half (46%) of the business owners or IT decision makers are confident in employees’ ability to take necessary steps to protect company devices and IP.
- A majority (68%) of small business owners believe their cybersecurity risks are increasing.
- One-third (30%) of the small businesses that experienced cyberattacks reported the attacks occurred due to a vulnerability in outdated or unpatched software that was breached.
Resources for Small Businesses' Digital Defense
In an increasingly complex online world, the need for resources and products to help keep small business owners and their employees informed and protected online has never been greater.
McAfee’s Business Protection is a comprehensive security solution built specifically for small business owners to ensure comprehensive protection for employees, data, devices, and online connections. Launched in collaboration with Dell Technologies last year, the software helps small business customers stay ahead of cyber threats and vulnerabilities with award-winning security, identity monitoring on the dark web, VPN, web protection for safe browsing, and more. In addition to the security features McAfee Business Protection has also been designed to be extremely intuitive and is easy to use with automated protections, timely alerts, and simple user interface.
“We understand the vulnerabilities and risks small business owners face, and we’re committed to providing them industry leading online protection solutions that let them do what they do best and let us do what we do best – protect you, your data, and your customers,” said Pedro Gutierrez, Senior Vice President of Sales for McAfee.
In addition, to help educate small business professionals about the growing cyber threat landscape, and to arm them with tips to keep their data, employees, customers and livelihoods safe, McAfee and Dell have prepared a free small business resource guide.
About McAfee and Dell’s Global Small Business Study
The survey reflects the answers of 700 Business owners and IT professionals. Respondents were either top management or IT decision makers working for an organization with less than 250 employees. Respondents came from 6 countries: US, UK, Germany, France, Japan, and Australia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116065441/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
